FAAH genetic variation enhances fronto-amygdala function in mouse and human

Citations Over TimeTop 1% of 2015 papers

Abstract

Cross-species studies enable rapid translational discovery and produce the broadest impact when both mechanism and phenotype are consistent across organisms. We developed a knock-in mouse that biologically recapitulates a common human mutation in the gene for fatty acid amide hydrolase (FAAH) (C385A; rs324420), the primary catabolic enzyme for the endocannabinoid anandamide. This common polymorphism impacts the expression and activity of FAAH, thereby increasing anandamide levels. Here, we show that the genetic knock-in mouse and human variant allele carriers exhibit parallel alterations in biochemisty, neurocircuitry and behaviour. Specifically, there is reduced FAAH expression associated with the variant allele that selectively enhances fronto-amygdala connectivity and fear extinction learning, and decreases anxiety-like behaviours. These results suggest a gain of function in fear regulation and may indicate for whom and for what anxiety symptoms FAAH inhibitors or exposure-based therapies will be most efficacious, bridging an important translational gap between the mouse and human.

Related Papers

• → Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system(2003)301 cited
• → Alterations in the Endocannabinoid System in Schizophrenia(2020)2 cited
• → Inhibitors of Endocannabinoid Degradation as Potential Therapeutic Agents: An Update(2004)
• → Natural Endocannabinoid Derivatives as Templates for the Development of FAAH Inhibitors(2005)
• → Fatty acid amide hydrolase, anandamide, and neurological diseases(2023)